Suppressing fatal disease outside muscle may preserve a mimetic’s lifespan benefit
A substance that mimics fasting may extend animal lifespan by suppressing fatal disease outside muscle despite blocked muscle recovery. The hypothesis fails if restoring muscle recovery restores a lost survival benefit while disease in other tissues remains comparable
Stage of verification
- Hypothesis published2026-10-06
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
The biological function description is being prepared
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Metabolism and energy
Anabolism
The cellular processes that build biological components and support growth and rebuilding
Where this hypothesis actsMuscle during recovery between cycles of fasting-mimetic treatment
Hypotheses on this target 1
Inhibition1
Activation
Function preservation
Supplementation
Feedback restoration
Direct measurement
What is proposed
Inhibition
Selectively suppress the recovery of muscle anabolism between treatment cycles
With whatNot stated in the record
HowA moderate, selective muscle intervention while maintaining mimetic target suppression in other tissues; the specific technique is not stated
Possible result
Expected retention of the mimetic's additional lifespan benefit despite reduced muscle strength and anabolic response
From the recordпри умеренном избирательном устранении восстановительной фазы миметик сохранит дополнительный выигрыш жизни
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
An intervention might help animals live longer even while leaving their muscles less able to recover between treatments. The unexpected move is to separate protection against fatal disease outside muscle from the rebuilding of muscle: the former would provide extra life, while the latter would improve how well treatment is tolerated. That separation is a hypothesis generated by the pipeline, not a measured result.
- The fasting-like intervention is proposed to suppress potentially fatal disease outside muscle, such as tumor growth.
- That disease suppression is proposed to delay death and provide most of the intervention's extra lifespan.
- Selective reduction of muscle rebuilding between cycles is predicted to weaken muscle recovery without removing protection in other tissues.
- The intervention is therefore predicted to retain its additional lifespan benefit compared with animals receiving the same muscle intervention alone.
- Restoring muscle recovery is predicted to improve muscle function while changing the additional lifespan benefit little.
A building could remain standing longer because fire prevention improves, even while routine repairs become less effective. Better repairs would make it more usable without necessarily adding much to the protection against fire.
Where the picture breaks: Muscle and other tissues interact, so their contributions cannot be assumed to remain separate like maintenance tasks. Establishing that separation is the central biological claim.
- Master questionstep 01 of 04
Reproducing selected natural bodily processes might provide new ways to extend life through substances, combinations or other interventions.
Rests on: The goal is to generate explanations of which natural processes could be reproduced and why their effects might extend life.
AssumptionThe search assumes that useful effects of natural processes can be reproduced by an intervention and might extend life; the goal itself does not establish either outcome.
- Goal pillarstep 02 of 04
Repeated treatments bring attention to whether the body's response completes its cycle before the next treatment.
Rests on: The broad search for interventions is narrowed to the completion of repeated responses.
AssumptionCompletion of repeated response cycles is selected as a potentially relevant feature of life-extending interventions. The master question does not supply a reason for choosing this feature.
- Gap questionstep 03 of 04
A fasting-like intervention might still extend life when muscle rebuilding between treatment cycles is selectively removed, provided its main biological target remains equally suppressed in other tissues.
Rests on: The preceding stage identifies completion of repeated response cycles as the subject of interest.
AssumptionMuscle rebuilding is selected as the recovery phase to examine. The question assumes that this phase can be selectively removed while preserving the intervention's target suppression elsewhere; no method establishing that separation is supplied.
- Hypothesisstep 04 of 04
Suppression of fatal disease outside muscle could provide most of the extra lifespan, while muscle recovery separately improves treatment tolerance. A proposed intervention would therefore limit its effects on muscle protein production while retaining protection against tumors elsewhere.S1S2
Rests on: Biomolecules (2023) reports that ethyl 3-hydroxybutyrate, the compound administered in that study, improved muscle condition and survival and reduced tumor weight in mice with cancer-associated wasting; those simultaneous changes do not separate their contributions to survival. Cell Metabolism (2015) reports longer life and fewer cancers with repeated fasting-like diet cycles, but does not establish that cancer reduction causes the lifespan benefit or that the benefit survives selective removal of muscle recovery.
Supported by literature
What is carried, and what is not. Of the five proposed mechanism links listed here, the supplied literature speaks to the first two through reports connecting treatment, less disease and longer survival, rather than establishing those causal links. For example, Cell Metabolism (2015) reports fewer cancers alongside longer life after fasting-like diet cycles, but neither it nor another supplied source establishes the full sequence with muscle recovery selectively removed.
Where the reasoning is carried by something unstated · 3
- Master question. The search assumes that useful effects of natural processes can be reproduced by an intervention and might extend life; the goal itself does not establish either outcome.
- Goal pillar. Completion of repeated response cycles is selected as a potentially relevant feature of life-extending interventions. The master question does not supply a reason for choosing this feature.
- Gap question. Muscle rebuilding is selected as the recovery phase to examine. The question assumes that this phase can be selectively removed while preserving the intervention's target suppression elsewhere; no method establishing that separation is supplied.
How a result here could mislead · 3
- Failure to detect a difference could be mistaken for preservation of the lifespan benefit. A weakly informative comparison could miss either a meaningful loss or the enhancement predicted by one rival. What closes it: Use the proposed four groups to compare the extra lifespan attributable to treatment with and without the muscle intervention. Set the equivalence band, the range of differences considered small enough to count as preservation, before the experiment and assess whether the uncertainty fits inside it. No numerical band, sample size or lifespan comparison measure is supplied.
- A retained benefit could reflect incomplete removal of muscle recovery. A lost benefit could instead reflect changed treatment action outside muscle, or disruption of muscle functions beyond rebuilding. What closes it: Measure suppression of muscle rebuilding and the intended effect on strength, and verify unchanged suppression of the treatment's main target in other tissues. The muscle intervention must also be characterized for effects on the competing repair processes described by the rivals; the supplied specification does not identify an intervention that isolates rebuilding from those processes.
- Fewer fatal tumors alongside longer survival could be credited with causing the survival benefit even if both are parallel effects of treatment. Preservation alone would show that full muscle recovery is unnecessary under the tested conditions, not that tumor suppression supplies most of the extra life. What closes it: Determine causes of death through the proposed examination of tissues after death and track fatal disease outside muscle. Attribution of most of the lifespan benefit to disease suppression requires evidence that separates its contribution from other treatment effects; the four-group comparison alone does not provide that separation.
What would make this wrong. The proposed separation would be contradicted if selectively reducing muscle recovery removed the intervention's lifespan benefit, and selectively restoring muscle recovery brought that benefit back while disease outside muscle remained comparable. A clearly increased benefit after reducing muscle recovery would instead contradict the specific prediction of preservation within the pre-established equivalence band.
What it would change. If the prediction held, completing muscle recovery would not be necessary for the full lifespan benefit of the tested fasting-like intervention under those conditions. The search for new interventions could then distinguish the components that prevent fatal disease from those that preserve muscle function and treatment tolerance. That result would still not establish that tumor suppression is the main cause of longer life, identify a working new compound, or establish lifespan extension in humans.
Sources read · 7
Exploring the Therapeutic Potential of Ethyl 3-Hydroxybutyrate in Alleviating Skeletal Muscle Wasting in Cancer Cachexia. · Biomolecules · 2023
“The administration of EHB alleviated cachexia-related symptoms, ameliorated skeletal muscle atrophy, and improved survival in cachectic mice. In addition, the supplementation of cachectic mice with 3-HB by EHB administration significantly reduced tumor weights, indicating the anti-tumor effects of 3-HB.”
Does not settle: Источник одновременно сообщает об улучшении состояния мышц, снижении массы опухолей и повышении выживаемости у мышей с раковой кахексией, но не разделяет вклад этих эффектов. Он не проверяет сохранение выигрыша в продолжительности жизни при избирательном подавлении восстановления мышц, не устанавливает причинное посредничество опухолевого эффекта и не исследует SPV_8.
A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. · Cell metabolism · 2015
“Bi-monthly FMD cycles started at middle age extended longevity, lowered visceral fat, reduced cancer incidence and skin lesions, rejuvenated the immune system, and retarded bone mineral density loss.”
Does not settle: The source does not test selective suppression of muscle anabolic recovery, separate muscle restoration from effects in other tissues, establish that reduced cancer incidence mediates the lifespan benefit, or compare lifespan under the same muscle intervention with FMD versus control.
[Anti-aging effects by caloric restriction]. · Nihon rinsho. Japanese journal of clinical medicine · 2009
“Caloric restriction (CR) in experimental animals shows to extend the lifespan of animals with the decreased frequency of age-related diseases.”
Does not settle: Источник не устанавливает, обусловлено ли продление жизни подавлением опухолевой патологии вне мышц, и не исследует мышечный анаболизм, восстановление мышц, избирательное устранение восстановительной фазы миметика, противоопухолевое действие в отдельных тканях или показатель SPV_8.
Identification of potential caloric restriction mimetics by microarray profiling. · Physiological genomics · 2005
“We have shown that CR initiated late in life begins to extend lifespan, reduce cancer as a cause of death, and reproduce approximately three-quarters of the genomic effects of LTCR in 8 wk (CR8).”
Does not settle: Источник не устанавливает причинную роль подавления опухолей в продлении жизни и не исследует мышечный анаболизм, восстановление мышц, переносимость воздействия, избирательное вмешательство в мышечную трансляцию или SPV_8.
Metabolic regulation of Sirtuins upon fasting and the implication for cancer. · Current opinion in oncology · 2013
“In addition, fasting or 10–30% decrease in calorie intake increases lifespan up to 50% and prevents carcinogenesis in spontaneous, chemical or radiation-induced tumorigenesis in several mammalian experimental models [ – ].”
Does not settle: Источник оставляет открытыми независимость продления жизни от восстановления мышц, вклад подавления опухолей в выживаемость, эффекты избирательного устранения восстановительной фазы и действие предлагаемого миметика.
Longevity and skeletal muscle mass: the role of IGF signalling, the sirtuins, dietary restriction and protein intake. · Aging cell · 2015
“Optimizing dietary restriction (DR) or using DR mimetics in combination with amino acid administration may be critical interventions to help attenuate SkM loss with advancing age, while enabling healthy aging.”
Does not settle: The source does not test a mimetic with selectively reduced muscle-restorative activity, compare its lifespan effect with a matched muscle intervention plus control exposure, or establish that extra lifespan arises mainly from suppressing fatal disease outside muscle. It also does not evaluate SPV_8.
Sexually Dimorphic Response to Dietary Restriction-induced Longevity and Muscle Rejuvenation in Nothobranchius furzeri. · bioRxiv : the preprint server for biology · 2026
“Together, these findings demonstrate that IF promotes longevity and muscle health through conserved anabolic mechanisms alongside sex-specific cellular and molecular rejuvenation strategies.”
Does not settle: The source does not test whether longevity persists after selectively eliminating muscle recovery, whether muscle anabolism is causally required for lifespan extension, or whether suppression of tumors or other fatal extra-muscular pathology independently mediates the lifespan benefit.
The gap this hypothesis explains
Two live hypotheses pull in opposite directions here, and the field has not chosen between them.
Does a fasting-like treatment still extend life if muscle rebuilding cannot recover between treatments?
Original wording · exactly as the pipeline generated it
Сохранит ли миметик голодания продление жизни при избирательном устранении межциклового восстановления мышечного анаболизма, если подавление его основной мишени в остальных тканях остаётся прежним?
What this question is asking
The question asks whether a treatment's life-extending effect depends on muscles regaining their ability to build proteins between treatment cycles. It concerns a fasting mimetic, meaning a treatment intended to reproduce some effects of fasting, whose stated target is mechanistic target of rapamycin, or mTOR, a regulator of cell growth and metabolism. The comparison is between the same treatment with muscle recovery preserved and with that recovery selectively prevented, while target suppression in other tissues remains unchanged. The pipeline assumes that intermittent target suppression extends mouse lifespan and asks whether this benefit survives the loss of muscle recovery. Its stated recovery requirement is that muscles respond again by the next usual physical load and that repeated treatment does not lengthen their period of reduced responsiveness.
- Fasting mimetic
- A treatment intended to reproduce some biological effects of fasting. This names a class of intended effects, not a single substance or a guarantee that all effects of fasting are reproduced.
- Mechanistic target of rapamycin (mTOR)
- A regulator involved in cell growth and metabolism. The pipeline identifies its suppression as the treatment's main action.
- Mechanistic target of rapamycin complex 1
- A signaling assembly containing the target regulator that participates in controlling growth and protein building. S1 connects its activity to nutrient availability; S3 shows that sustained signaling need not mean sustained muscle protein production.
- Muscle anabolism or muscle rebuilding
- The building side of muscle maintenance, including production of muscle proteins. Recovery here means restoration of that building response between treatments, not necessarily a demonstrated increase in muscle size.
- Muscle protein synthesis
- The production of new proteins in muscle. It is a process contributing to muscle rebuilding, rather than a direct measurement of lifespan.
- Reduced responsiveness
- A smaller protein-building response despite continued stimulation. S3 describes this phenomenon, but does not establish its duration across the proposed treatment cycles.
- Essential amino acids and leucine
- Essential amino acids are protein building blocks that must come from the diet; leucine is one of them. S1 discusses their availability as an influence on growth-related signaling.
- Skeletal muscle and resistance training
- Skeletal muscles produce body movement. Resistance training loads these muscles against resistance, and S2 links their subsequent recovery to temporary increases in protein production.
- Ribosomes
- The cellular machinery that builds proteins. S4 relates their abundance to the capacity for muscle recovery after early undernutrition.
- Catch-up growth
- Accelerated growth during recovery from an earlier growth shortfall. In S4 it concerns development after undernutrition, rather than recovery between fasting-like treatment cycles.
- Myotis lucifugus and hibernation
- Myotis lucifugus is the bat species studied in S7. Hibernation includes periods of greatly reduced bodily activity; the supplied description concerns predicted signaling changes during that state.
- Rapamycin
- A substance described in S8 as inhibiting mechanistic target of rapamycin signaling. Its reported survival effect concerns the particular disease-model mice studied there.
- Fxn conditional inactivation and Friedreich ataxia model
- S8 concerns mice in which the gene identified as Fxn was switched off in selected tissues to model aspects of Friedreich ataxia, a disease. This specific altered background limits what its survival finding establishes about ordinary aging.
- RL-1
- An identifier supplied by the pipeline alongside its claim about intermittent target suppression and mouse lifespan. The provided material does not establish what it denotes.
Intermittent mTOR suppression, identified in the pipeline as RL-1, is associated with longer mouse lifespan, and muscle rebuilding recovers between cycles without a progressively longer period of reduced responsiveness.
The assumption concerns mice receiving repeated treatment that temporarily suppresses a regulator of cell growth. It treats longer life and recovery of muscle protein building before the next usual physical load as the starting conditions. If those conditions hold, the remaining question is whether removing muscle recovery removes the lifespan benefit.
The supplied sources do not establish this starting combination. S1 and S2 concern protein building around exercise, and S3 describes reduced responsiveness of muscle protein production despite continued nutrient availability and growth-related signaling. S8 reports improved survival after target suppression in mice with a specific disease-related genetic alteration, which does not establish longer natural lifespan under the intermittent treatment described here. The supplied search results contain no work establishing the RL-1 claim or stable recovery across repeated treatment cycles; this does not show that either claim is false.S1S2S3S8
The same question asked without the part nothing read establishes:
- During intermittent suppression of mechanistic target of rapamycin, does preventing muscle rebuilding from recovering between cycles change lifespan when suppression in other tissues stays the same?
- Does a fasting-like treatment's effect on lifespan depend on muscle rebuilding recovering between treatment cycles?
- The lifespan benefit is preserved If a lifespan benefit is first established and remains unchanged when muscle recovery is selectively prevented, that recovery would not be necessary for the benefit under those conditions. This would establish a separation between the lifespan outcome and that particular muscle response, without establishing that muscle health is unaffected.
- The lifespan benefit disappears If selective prevention of recovery removes an established lifespan benefit while suppression elsewhere stays unchanged, that would support a necessary contribution from muscle recovery under those conditions. Continued target suppression in other tissues would then be insufficient to preserve the benefit.
- The lifespan benefit becomes smaller If preventing recovery reduces but does not eliminate an established benefit, muscle recovery would contribute to its magnitude without accounting for all of it. The remaining extension of life would show that some benefit persists without that recovery, while leaving its explanation unsettled.
The proposed chain begins with temporary suppression of a growth-regulating target, followed by an interval in which muscle protein building can recover. Temporary increases in muscle protein production after exercise contribute to muscle growth, according to S2. Whether that recovery also helps preserve a treatment's lifespan benefit is a separate causal link that the supplied sources do not establish. If recovery is necessary, treating target suppression alone as sufficient would misidentify what produces the benefit. If recovery is unnecessary for that benefit, assuming otherwise would incorrectly make muscle recovery a condition for life extension.
Импульсное подавление mTOR, RL-1, связано с продлением жизни мышей; необходимость восстановительной фазы причинно не установлена.
Мышечный ответ восстанавливается до следующей обычной нагрузки; период нечувствительности не увеличивается при повторении.
Неизвестно, исчезает ли выигрыш продолжительности жизни при избирательном устранении восстановления и сохранении остальных эффектов миметика.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Обязательная связь между восстановлением мышечного анаболизма и продлением жизни миметиком может отсутствовать. Выигрыш жизни создаётся преимущественно подавлением смертельной патологии вне мышцы, например замедлением опухолевого роста, тогда как восстановление мышцы независимо улучшает переносимость воздействия. Следовательно, при умеренном избирательном устранении восстановительной фазы миметик сохранит дополнительный выигрыш жизни относительно животных с тем же мышечным вмешательством, получающих контрольное воздействие. Физиологический прототип включает ограничение избыточного роста; мышечное восстановление является отдельным полезным компонентом. Новый миметик мог бы сочетать ограниченное действие на мышечную трансляцию с сохранением противоопухолевого эффекта в других тканях. Такое разделение поддерживало бы SPV_8, хотя этот показатель здесь не является обязательным посредником долголетия.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
В факторном сравнении миметика и мышечного блокирования последнее ухудшит силу и анаболический ответ, но дополнительный выигрыш жизни от миметика сохранится в заранее установленной полосе эквивалентности. Снижение частоты или отсрочка смертельных опухолей также сохранится. Восстановление мышечной функции улучшит функциональные показатели, почти не изменив дополнительного выигрыша жизни. Гипотеза опровергается, если избирательное возвращение мышечного восстановления возвращает утраченный эффект миметика на выживаемость при сопоставимой патологии остальных тканей.
Would tell it apart from at least one rival. The prediction specifies directional outcomes, preservation of lifespan benefit within a predefined equivalence band, and an explicit rejection condition. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Нужны четыре основные группы: контроль, миметик, мышечное вмешательство и их сочетание. Причины смерти определяются патологоанатомически. Отсутствие статистически значимого взаимодействия само по себе недостаточно; требуется оценка допустимого размера потери эффекта.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
В факторном сравнении миметика и мышечного блокирования последнее ухудшит силу и анаболический ответ, но дополнительный выигрыш жизни от миметика сохранится в заранее установленной полосе эквивалентности. Снижение частоты или отсрочка смертельных опухолей также сохранится. Восстановление мышечной функции улучшит функциональные показатели, почти не изменив дополнительного выигрыша жизни. Гипотеза опровергается, если избирательное возвращение мышечного восстановления возвращает утраченный эффект миметика на выживаемость при сопоставимой патологии остальных тканей.
- Rival 01 of 04What would separate them
Mismatched ribosome assembly may make muscle recovery limit fasting-mimetic lifespan gains predicts: При подтверждённом подавлении межциклового синтеза белка мышечно-специфическое вмешательство увеличит дополнительный выигрыш жизни от миметика и уменьшит долю рибосомных белков вне собранных рибосом. Принудительное восстановление анаболического всплеска вернёт протеотоксичность и сократит этот выигрыш. Решающий результат: согласование сборки рибосом устранит вред всплеска при сохранении его амплитуды. Если блокирование восстановления сокращает жизнь при нормальной сборке рибосом, гипотеза уступает механизмам обязательного структурного или органелльного восстановления.
- What would separate them
Persistent muscle stromal cells may erase lifespan gains from fasting mimetics predicts: После блокирования межциклового анаболизма численность фиброзно-жировых предшественников начнёт увеличиваться от цикла к циклу раньше выраженного фиброза. Избирательное возвращение их численности к физиологическому диапазону восстановит выигрыш жизни при сохранённом подавлении мышечного синтеза белка. Краткое восстановление анаболизма поможет только до закрепления патологической структуры сообщества. Если численность и судьба этих клеток остаются нормальными, а их избирательное ограничение не помогает, гипотеза уступает внутриклеточным механизмам.
- What would separate them
Incomplete sarcomere repair may erase a fasting mimetic's lifespan benefit predicts: При одинаковом подавлении общего синтеза белка потеря эффекта миметика будет зависеть от механической нагрузки и сопровождаться незавершённой заменой филамина C в Z-дисках. Избирательное восстановление его встраивания улучшит удельную силу и сохранит выигрыш жизни при низком общем анаболизме. Нормализация только численности стромальных клеток или только лизосомного цикла окажется недостаточной. Сохранность Z-дисков и отсутствие зависимости от нагрузки при утрате выигрыша жизни опровергнут этот механизм.
- What would separate them
Failed lysosome reformation may erase a fasting mimic's lifespan benefit predicts: Продолжительное подавление мышечного mTORC1 уменьшит повторное образование лизосом, ухудшит деградацию аутофагического груза в поздних циклах и устранит выигрыш жизни. При сопоставимом подавлении синтеза белка через отдельную трансляционную ветвь, сохраняющую лизосомный цикл, выигрыш останется. Восстановление именно преобразования мембран аутолизосом вернёт эффект миметика при низком анаболизме. Если оба способа подавления трансляции одинаково сокращают жизнь при нормальной лизосомной функции, гипотеза уступает структурному механизму.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.